MicroRNAs to take the place of collateral flow index measurements and Rentrop scoring?—Reply to Papageorgiou et al.

We thank Papageorgiou et al. for their thoughtful comments on our recent publication regarding circulating microRNAs (miRNAs) associated with coronary collateral artery capacity (1). The benefits of a vast collateral network have been widely accepted to prevent mortality in patients with chronic stable coronary artery disease (CAD) (2,3). Identifying patients with a limited collateral network can in turn distinguish patients at risk to substantial debilitation from adverse cardiac events. Nonetheless, current methods to identify patients with insufficient collateralization are limited to invasive intracoronary collateral flow index (CFI) measurements or angiographic grading (4). Clinical parameters associated with collateral development have been identified (5). However, there remained a lack of biomarkers to discriminate between patients with sufficient or insufficient collateralization.

Genetic heterogeneity in CAD patients has been identified at the messenger RNA level of circulating monocytes and macrophage phenotypes (6,7). This led us to hypothesize that differential miRNA expression in patients with insufficient vs. sufficient collateralization must also be present. We identified 4 miRNAs that were significantly upregulated in the plasma of patients with low collateral capacity. We further determined that these miRNAs (miR423-5p, miR10b, miR30d, miR126) could serve as circulating biomarkers to significantly distinguish between chronic total occlusion (CTO) patients with high or low collateral capacity. These miRNAs can discriminate between these patient groups with a positive likelihood ratio between 3.0 and 6.1 depending on the respective miRNA. This revelation can be of immense clinical significance, whereby patients with low collateralization can be potentially identified with a simple blood sample rather than invasive intracoronary catheterization. However, our study warrants further studies with larger patient cohorts, along with examining the utility of these miRNAs as biomarkers for collateralization in CAD patients.

Papageorgiou et al. point out that the utility of these miRNAs is also dependent on a generally accepted definition of low collateral capacity, whereby some studies use Rentrop scoring and others use different thresholds of pressure-derived CFI (CFI_p) to establish the level of collateralization. Rentrop scoring provides only a semi-quantitative measure and is limited to collateral vessels above 100 µm diameter. In relation to CFI_p measurements, it is important to recognize the difference between CAD and CTO patients, whereby CTO patients provide no variability in coronary lesion severity as compared to CAD patients. As a result, the distribution of CFI_p measurements in CTO patient populations differs from that in CAD patients. The mean CFI_p in a cohort of 295 patients was deemed to be 0.39 (5), while in CAD patients the frequency distribution of CFI_p is dependent on the severity of CAD (2).

As both Papageorgiou et al. and we have mentioned, a number of co-existing parameters may affect the diagnostic ability of miRNAs in the general population. Medication usage, gender, age as well as diabetes mellitus have been shown to affect both collateral vessel development as well as miRNA expression levels (8-11). In our study, gender and age significantly impacted the predictive power of the respective miRNAs as suitable biomarkers. However, miR126 demonstrated significant predictive power to discriminate between patients with high and low collateral capacity even without consideration of age and gender. MiRNA126 has been largely linked to angiogenesis, as well as atherosclerosis, whereby the mature miRNA-126-5p plays a role in endothelial turnover (12). Examining larger patient cohorts will likely elucidate the exact threshold of the respective miRNA expression levels that can distinguish between these patient groups, and provide additional insight in the effects of other co-existing parameters on this threshold.

In conclusion, circulating miRNAs offer a new method for patient stratification. Nonetheless, there still remains a large step before miRNA examination can become a part of routine clinical application. As the possibility to distinguish the coronary collateral artery capacity of patients without the need for invasive catheterization is of great clinical significance, our results warrant further investigation in larger CTO patient cohorts, along with examining the predictive power of these miRNAs in CAD patients.

Acknowledgements

Funding: This work was performed within the framework of CTMM, Center for Translational Molecular Medicine (www.ctmm.nl), project EMINENCE (grant 01C-204).

Footnote

Provenance: This is a Guest Letter to the Editor commissioned by Section Editor Zhijun Han, MD (Department of Laboratory Medicine, Wuxi Second Hospital, Nanjing Medical University, Wuxi, China).

Conflicts of Interest: The authors have no conflicts of interest to declare.

Response to: Papageorgiou N, Zacharia E, Tousoulis D. Association between microRNAs and coronary collateral circulation: is there a new role for the small non-coding RNAs? Ann Transl Med 2016;4:223.

References

1. Hakimzadeh N, Nossent AY, van der Laan AM, et al. Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function. PLoS One 2015;10:e0137035. [Crossref] [PubMed]
2. Meier P, Gloekler S, Zbinden R, et al. Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation 2007;116:975-83. [Crossref] [PubMed]
3. Meier P, Seiler C. The coronary collateral circulation--clinical relevances and therapeutic options. Heart 2013;99:897-8. [Crossref] [PubMed]
4. Hakimzadeh N, Verberne HJ, Siebes M, et al. The future of collateral artery research. Curr Cardiol Rev 2014;10:73-86. [Crossref] [PubMed]
5. van der Hoeven NW, Teunissen PF, Werner GS, et al. Clinical parameters associated with collateral development in patients with chronic total coronary occlusion. Heart 2013;99:1100-5. [Crossref] [PubMed]
6. Schirmer SH, Fledderus JO, Bot PT, et al. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res 2008;102:1286-94. [Crossref] [PubMed]
7. van der Laan AM, Schirmer SH, de Vries MR, et al. Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. Eur Heart J 2012;33:1076-84. [Crossref] [PubMed]
8. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010;107:677-84. [Crossref] [PubMed]
9. Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010;106:1035-9. [Crossref] [PubMed]
10. Dimmeler S, Nicotera P. MicroRNAs in age-related diseases. EMBO Mol Med 2013;5:180-90. [Crossref] [PubMed]
11. Epstein SE, Lassance-Soares RM, Faber JE, et al. Effects of aging on the collateral circulation, and therapeutic implications. Circulation 2012;125:3211-9. [Crossref] [PubMed]
12. Schober A, Nazari-Jahantigh M, Wei Y, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014;20:368-76. [Crossref] [PubMed]